Graphium biosciences inc
WebMalachite Innovations, Inc. 200 Park Avenue, Suite 400 Cleveland, Ohio 44122 (216) 304-6556. Transfer Agent. Securities Transfer Corporation 2901 Dallas Parkway, Suite 380 Plano, Texas 75093 (469) 633-0101 ... WebApr 6, 2024 · Malachite Innovations, Inc. FY 2024 revenue was $4.8 million compared to $0 of revenue reported for the four calendar yea... Malachite Innovations FY22 Revenue Grows To $4.8M, Achieving More Than Its Total Revenue Over Its Previous 10 Years Of …
Graphium biosciences inc
Did you know?
WebGraphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid … WebDec 28, 2024 · Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel …
WebApr 13, 2024 · Malachite Innovations Inc Actions Add to watchlist Add to portfolio Add an alert Price (USD)0.19 Today's Change0.00 / 0.00% Shares traded23.82k 1 Year change-46.48% Beta2.5872 Data delayed at... WebAvidity Biosciences, Inc. San Diego Metropolitan Area 10 minutes ago Be among the first 25 applicants See who Avidity Biosciences, Inc. has hired for this role
WebDec 28, 2024 · Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating … WebApr 5, 2024 · Graphium Biosciences, Inc. (“Graphium”) is a cannabinoid-based drug development company tracing its history of technological innovation and drug …
Web4.4K 52-Wk Range 0.1201 - 0.2986 (04/28/22 - 10/11/22) 33.22% Historical Volatility 149.3% Market Cap 12.5M Shares Outstanding 78.1M EPS (TTM, GAAP) -0.03 P/E Ratio (TTM, GAAP) -- Annual Dividend/Yield No dividend Ex-dividend Date No dividend Dividend Pay Date No dividend Beta 2.6 % Held by Institutions 0.10 Short Interest --
WebLatest Graphium Biosciences, Inc. Patents: CANNABINOID GLYCOSIDES AND USES THEREOF CANNABINOID GLYCOSIDE PRODRUGS AND METHODS OF … fmt mobility specialistWebDec 28, 2024 · CLEVELAND, OHIO, Dec. 28, 2024 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) announces that its wholly-owned drug development subsidiary, Graphium Biosciences, Inc., has been ... fmt malaysia newsWebThe meaning of GRAPHIUM is a form genus of imperfect fungi (family Stilbellaceae) with dark-colored coremia many of which (as the parasite of Dutch elm disease) have been … greensky.com loginWebInvestors. Graphium Biosciences. News and Events. 2024 ANNUAL REPORT HIGHLIGHTS. CLEVELAND, OHIO – (April 5, 2024) – MALACHITE INNOVATIONS, … greensky.com login accountWebOct 12, 2024 · Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating … fmtm crewWebAug 19, 2024 · Malachite Innovations, Inc. is a holding company. The Company is engaged in improving the health and wellness of people. The Company operates through its subsidiaries Graphium Biosciences, Inc. and Daedalus Ecosciences, Inc. Graphium Biosciences, Inc. focused its business activities on the health and wellness of people, … fmt medicationWebDec 31, 2024 · Graphium Biosciences, Inc. (“Graphium”) is a cannabinoid-based drug development company tracing its history of technological innovation and drug advancement back to October 2011 through two predecessor entities, Stevia First Corp. and Vitality Biopharma, Inc. In October 2024, Malachite formed Graphium as a wholly-owned … greensky.com/consumer